Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements

Journal of Neuroscience

Volumn 27, Issue 34, 2007, Pages 9115-9129

  Asuni, Ayodeji A ^a   Boutajangout, Allal ^a   Quartermain, David ^a   Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Immunization; P301L; Tangles; Tau; Transgenic mice

Indexed keywords

ANTIGEN; PROTEIN ANTIBODY; PROTEIN P30; TAU PROTEIN;

ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; BEHAVIOR, ANIMAL; BRAIN; CELL LINE, TUMOR; DEMENTIA; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; LEUCINE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROBLASTOMA; PROLINE; PSYCHOMOTOR PERFORMANCE; RECOGNITION (PSYCHOLOGY); SEX FACTORS; TAU PROTEINS;

EID: 34548146119     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2361-07.2007     Document Type: Article

References (71)

1. Aihara N, Tanno H, Hall JJ, Pitts LH, Noble LJ (1994) Immunocytochemical localization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J Comp Neurol 342:481-496.
2. Andoh T, Kuraishi Y (2004) Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. FASEB J 18:182-184.
3. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25:5446-5454.
4. Asuni AA, Knudsen E, Frangione B, Wisniewski T, Sigurdsson EM (2004) Antibody mediated modulation of Aβ induced neurotoxicity in cell culture. Neurobiol Aging 25:S581-S582.
5. Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM (2006) Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages. Eur J Neurosci 24:2530-2542.
6. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid-β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23:2223-2226.
7. Broadwell RD, Sofroniew MV (1993) Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 120:245-263.
8. Carro E, Nunez A, Busiguina S, Torres-Aleman I (2000) Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 20:2926-2933.
9. Cataldo AM, Barnett JL, Pieroni C, Nixon RA (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J Neurosci 17:6142-6151.
10. Connell JW, Gibb GM, Betts JC, Blackstock WP, Gallo J, Lovestone S, Hutton M, Anderton BH (2001) Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3β identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. FEBS Lett 493:40-44.
11. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59:398-407.
12. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2:231-238.
13. Dietzschold B, Kao M, Zheng YM, Chen ZY, Maul G, Fu ZF, Rupprecht CE, Koprowski H (1992) Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci USA 89:7252-7256.
14. Fabian RH (1990) Uptake of antineuronal IgM by CNS neurons: comparison with antineuronal IgG. Neurology 40:419-422.
15. Fabian RH, Petroff G (1987) Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology 37:1780-1784.
16. Fabian RH, Ritchie TC (1986) Intraneuronal IgG in the central nervous system. J Neurol Sci 73:257-267.
17. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol 14:11-20.
18. Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB (2007) Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 9:139-148.
19. Goedert M (2004) Tau protein and neurodegeneration. Semin Cell Dev Biol 15:45-49.
20. Gonias SL, Wu LH, Salicioni AM (2004) Low density lipoprotein receptor-related protein: regulation of the plasma membrane proteome. Thromb Haemost 91:1056-1064.
21. Gotz J, Chen F, Barmettler R, Nitsch RM (2001a) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529-534.
22. Gotz J, Chen F, Van Dorpe J, Nitsch RM (2001b) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293:1491-1495.
23. Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acidtreated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267:564-569.
24. Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL (1990) Low-density-lipoprotein receptor-related protein mediates endocytosis of monoclonal-antibodies in cultured-cells and rabbit liver. J Biol Chem 265:21355-21362.
25. Iqbal K, Grundke-Iqbal I (2004) Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. Curr Drug Targets 5:495-502.
26. Jicha GA, Bowser R, Kazam IG, Davies P (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48:128-132.
27. Jicha GA, Berenfeld B, Davies P (1999) Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res 55:713-723.
28. Knopf PM, Harling-Berg CJ, Cserr HF, Basu D, Sirulnick EJ, Nolan SC, Park JT, Keir G, Thompson EJ, Hickey WF (1998) Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol 161:692-701.
29. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK (1995) LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation. Cell 82:331-340.
30. LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R, Zlokovic BV (2004) Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 138:233-242.
31. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul MM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402-405.
32. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
33. Liu HM, Atack JR, Rapoport SI (1989) Immunohistochemical localization of intracellular plasma proteins in the human central nervous system. Acta Neuropathol (Berl) 78:16-21.
34. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
35. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005a) Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131.
36. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005b) Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46:857-868.
37. Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI, Himes RH, Audus KL, Georg GI (2005) β-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 312:659-668.
38. Mohamed HA, Mosier DR, Zou LL, Siklos L, Alexianu ME, Engelhardt JI, Beers DR, Le WD, Appel SH (2002) Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 69:110-116.
39. Nerenberg ST, Prasad R (1975) Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 86:887-898.
40. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9:448-452.
41. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990-6995.
42. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332.
43. Otvos Jr L, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39:669-673.
44. Paris D, Town T, Parker TA, Tan J, Humphrey J, Crawford F, Mullan M (1999) Inhibition of Alzheimer's β-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp Neurol 157:211-221.
45. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 280:3628-3635.
46. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K (2001) Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:555-567.
47. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43:815-825.
48. Rapoport SI (2000) Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 20:217-230.
49. Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sanchez B, Nieto M, Gomez-Ramos P, Moran MA, Cabodevilla F, Samaranch L, Ortiz L, Perez A, Ferrer I, Avila J, Gomez-Isla T (2005) Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 20:814-822.
50. Rye DB, Leverenz J, Greenberg SG, Davies P, Saper CB (1993) The distribution of Alz-50 immunoreactivity in the normal human brain. Neuroscience 56:109-127.
51. Sahara N, Lewis J, McGowan E, Dickson DW, Hutton M, Yen SHC, Lee G (2002) Temporal expression and phosphorylation of tau in P301L mutant tau transgenic mice. Neurobiol Aging 23:S552-S553.
52. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-481.
53. Schenk D (2002) Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3:824-828.
54. Schmittgen TD, Zakrajsek BA (2000) Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RTPCR. J Biochem Biophys Methods 46:69-81.
55. Sigurdsson EM (2005) Histological staining of amyloid-β in mouse brains. Methods Mol Biol 299:299-308.
56. Sigurdsson EM (2006) Immunotherapy for conformational diseases. Curr Pharm Des 12:2569-2585.
57. Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM (1996) Local and distant histopathological effects of unilateral amyloid-β 25-35 injections into the amygdala of young F344 rats. Neurobiol Aging 17:893-901.
58. Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA (1997) Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging 18:591-608.
59. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001) Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159:439-447.
60. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J Neurosci 24:6277-6282.
61. Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Scholtzova H, Tsui WH, Li Y, Sadowski M, Turnbull DH, deLeon M, Wisniewski T (2007) A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging, in press.
62. Spillantini MG, Bird TD, Ghetti B (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 8:387-402.
63. Spires TL, Orne JD, Santacruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 168:1598-1607.
64. Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK (2007) Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. J Biol Chem 282:18895-18906.
65. Terry RD (1994) Neuropathological changes in Alzheimer disease. Prog Brain Res 101:383-390.
66. The TH, Feltkamp TE (1970) Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. Immunology 18:875-881.
67. Torres EM, Perry TA, Blockland A, Wilkinson LS, Wiley RG, Lappi DA, Dunnet SB (1994) Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 63:95-122.
68. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH (2003) Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50:293-302.
69. Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21:719-727.
70. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227-231.
71. Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, Davson H (1990) A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 107:263-270.